Nuvation Bio Inc. Earnings Per Share (Basic)
Nuvation Bio Inc. (NUVB) reported Earnings Per Share (Basic) of -$0.18 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- Nuvation Bio Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.18.
- Nuvation Bio Inc. earnings per share, basic for the quarter ending 2026-03-31 was $0.02.
- Nuvation Bio Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$106.26.
- Nuvation Bio Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.16.
- Nuvation Bio Inc. earnings per share, basic for fiscal 2025 was -$0.60.
- Nuvation Bio Inc. earnings per share, basic for fiscal 2024 was -$2.11.
- Nuvation Bio Inc. earnings per share, basic for fiscal 2023 was -$0.35.
- Nuvation Bio Inc. earnings per share, basic for fiscal 2022 was -$0.48.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.18 10-Q · filed 2026-08-06 | -$0.17 10-Q · filed 2026-08-06 | -$271.13 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$433.38 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | $0.02 10-Q · filed 2026-05-04 | -$90.20 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$252.36 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$424.76 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$106.26 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$269.04 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$442.01 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.60 10-K · filed 2026-03-02 |
| 2025-09-30 | -$0.16 10-Q · filed 2025-11-03 | -$336.09 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.49 10-Q · filed 2025-11-03 | -$640.03 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.17 10-Q · filed 2026-08-06 | -$0.33 10-Q · filed 2026-08-06 | -$477.05 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$628.97 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.16 10-Q · filed 2026-05-04 | -$303.77 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$454.58 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2030.84 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2024-12-31 | -$146.53 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$296.74 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$1939.20 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$2.11 10-K · filed 2026-03-02 |
| 2024-09-30 | -$0.15 10-Q · filed 2025-11-03 | -$1943.66 derived: net income ÷ weighted average shares · filed 2025-11-03 | -$2.11 10-Q · filed 2025-11-03 | -$2226.31 derived: net income ÷ weighted average shares · filed 2026-04-10 |
| 2024-06-30 | -$1.89 10-Q · filed 2025-08-07 | -$2.06 10-Q · filed 2025-08-07 | -$2157.67 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$2265.55 derived: net income ÷ weighted average shares · filed 2026-04-10 |
| 2024-03-31 | -$0.07 10-Q · filed 2025-05-07 | -$130.49 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$220.23 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$314.53 derived: net income ÷ weighted average shares · filed 2026-04-10 |
| 2023-12-31 | -$62.96 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$152.70 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$247.01 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$0.35 10-K · filed 2025-03-06 |
| 2023-09-30 | -$0.09 10-Q · filed 2024-11-06 | -$184.06 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$0.28 10-Q · filed 2024-11-06 | -$378.77 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2023-06-30 | -$0.09 10-Q · filed 2024-08-05 | -$0.19 10-Q · filed 2024-08-05 | -$289.03 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$413.60 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2023-03-31 | -$0.10 10-Q · filed 2024-05-14 | -$194.72 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$319.30 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$479.88 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2022-12-31 | -$95.39 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$219.99 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$380.64 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$0.48 10-K · filed 2024-02-29 |
| 2022-09-30 | -$0.12 10-Q · filed 2023-11-02 | -$285.40 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$0.39 10-Q · filed 2023-11-02 | -$505.38 derived: net income ÷ weighted average shares · filed 2023-11-02 |
| 2022-06-30 | -$0.16 10-Q · filed 2023-08-03 | -$0.26 10-Q · filed 2023-08-03 | -$380.80 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$487.40 derived: net income ÷ weighted average shares · filed 2023-11-02 |
| 2022-03-31 | -$0.10 10-Q · filed 2023-05-04 | -$219.11 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$325.29 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$420.36 derived: net income ÷ weighted average shares · filed 2023-11-02 |
| 2021-12-31 | -$119.48 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$225.71 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$320.75 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$0.44 10-K · filed 2023-03-15 |
| 2021-09-30 | -$0.11 10-Q · filed 2022-11-03 | -$200.97 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$0.32 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$0.09 10-Q · filed 2022-08-04 | -$0.21 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |